Chronic Pelvic Pain and Interstitial Cystitis Patients Soon to Have New Treatment Options with Formation of KevMed, LLC

Share Article

Synechion, Inc., a research and consulting company specializing in the prevention of adhesions - internal scars causing pain and other complications - has announced the formation of a new company, KevMed, LLC to commercialize break-through innovations for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain with very few effective treatment options currently available.

Chronic Pelvic Pain Treatment

KevMed

KevMed brings hope to 15 million pelvic pain sufferers.

Synechion Inc., a research and consulting company specializing in the field of surgical adhesion (internal scar tissue) prevention, has announced the formation of KevMed, LLC. KevMed will commercialize new technologies for the treatment of chronic pelvic pain and related disorders. Over 15 million patients in the U.S. suffer from chronic pelvic pain for which very few effective treatment options are available. KevMed’s technology will provide safe and non-invasive pain therapy for these patients.

Research conducted by Synechion through its patient support and advocacy organization, the International Adhesions Society (IAS), has revealed that vast numbers of primarily female patients, debilitated by chronic pelvic and abdominal pain, are poorly served by current medical approaches.

According to David Wiseman, PhD, Founder and President of KevMed, “The founding of KevMed is a natural extension of our work spanning more than two decades, which has helped to make valuable contributions to the field of surgical adhesions. Not only have we played a pivotal role in the development of a number of anti-adhesions products, but our work with the International Adhesions Society (IAS) led to the founding of the world’s first dedicated clinic for the treatment of adhesions and Complex Abdominal and Pelvic Pain Syndrome (CAPPS). Our ground-breaking research has allowed us to better understand the needs of the adhesions and chronic pelvic pain patient. To serve these unmet needs, we have established KevMed.”

Adds Wiseman, “Patients suffering from chronic pelvic pain require an integrated treatment approach from a multi-disciplinary clinical team. Companies like KevMed, with a strong understanding of these patients’ needs, can support the multi-disciplinary approach with innovative, patient-centric technology. Our track record in research and patient service places KevMed in a unique position to serve patients with chronic pelvic pain.”

Over 15 million patients in the USA suffer from a number of overlapping disorders that include pelvic pain, abdominal pain, Adhesion Related Disorder (ARD), bowel obstruction, endometriosis, interstitial cystitis (IC), painful bladder syndrome, irritable bowel syndrome (IBS), vulvodynia, dyspareunia (painful intercourse), dyschezia (painful defecation), adhesions, sacroiliac joint pain, pudendal neuralgia and pelvic floor dysfunction. Numerous patients undergo hysterectomy in an effort to alleviate their pain, only to discover that the procedure worsens their condition. In extreme cases, patients will also report fibromyalgia, temporomandibular joint (TMJ) disorders (TMD) and reflex sympathetic dystrophy (RSD) or complex regional pain syndrome (CRPS). KevMed’s mission is to provide safe and non-invasive pain therapy to these patients.

About Synechion, Inc. and the International Adhesions Society (IAS)
Synechion, Inc. is a consulting company specializing in the science and business of post-operative adhesions, founded by David Wiseman, PhD, MRPharmS, internationally recognized expert who has been making important product and scientific contributions to the field since 1987. The International Adhesions Society (IAS) was founded by Synechion, Inc. in 1996 in response to demand by pelvic pain patients seeking answers in a field that remains poorly understood by many patients and clinicians.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

David Wiseman, PhD
Visit website